Hesco's 2 new Class 1 drugs won the first new product of the year.

On August 18, Hesco announced that two innovative class 1 drugs were making new progress: HSK7653 tablets phase III clinical trials were ethically approved, HSK3486 emulsion clinical applications were accepted by the National Drug Administration;
HSK7653 tablets are long-acting inhibitors of the two peptidease-4 (DPP-4), a new class 1 drug developed by Hesco with independent intellectual property rights to be used to treat type 2 diabetes.
meters of intranet data show that the current domestic market has been approved for the DPP-4 inhibitors have 5, respectively, Sigletin, Shagritin, Viglitin, Liglitatin and Agritin, the original research drugs have been approved for import for many years, the first imitation in 2019 and 2020 have been approved for the market.
Figure 1: HSK7653 domestic clinical trial registration Source: Mienet China Drug Clinical Trials PublicIty Library HSK7653 tablets were approved for clinical approval in November 2017, in May 2018 in Beijing Concord Hospital Phase I clinical, Phase III clinical trial program recently obtained ethical approval from Peking University People's Hospital, plans to start screening and joining the group of patients in the fourth quarter of 2020.
HSK3486 emulsion injection is a new class 1 drug developed by Hesco with independent intellectual property rights, intended for surgical whole hemp induction, endoscopic sedation/anesthesia, ICU sedation and other adaptations.
the product is the classic narcotic drug propofol me-better, with a significant reduction in lipid dosage, basic injection pain, safe dose width and other advantages.
Figure 2: HSK3486 Emulsion Domestic Clinical Trial Registration Source: Mininet China Drug Clinical Trials Public Notice Bank HSK3486 Emulsion Currently 18 clinical trial studies have been registered in China, digestive endoscopic diagnosis and treatment of sedation and/or anesthesia, general anaesthetic induction 2 adaptations have completed Phase III clinical and declared to market, and are included in the priority review, is expected to be approved in 2020.
this time by the State Drug Administration accepted for the adaptive "full hemp maintenance" Phase III clinical trial application, if the relevant clinical trials are successful, will hopefully further broaden the product's adaptive, enhance market competitiveness.
Injection acetate capofen net belongs to echinoline drugs, with a broad antibacterial spectrum, long half-life, high binding rate with human serum protein, fewer adverse reactions, good patient tolerance and so on, is a clinically urgent need for anti-deep fungal infection drugs. according to
meters of intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal injection acetate carpofen net sales of more than 2 billion yuan, Hesco is the fourth domestic enterprise of the same breed to obtain a certificate of registration, the product is also the first generic drug approved by Hesco in 2020 to date.
.